LIVIVO - Search results -

Search results

Result 1 - 10 of total 23

Search options

Article ; Online: The Importance of Genomic Context in Interpreting Fosfomycin Resistance in Klebsiella pneumoniae.

Kieffer, Nicolas / Guzmán Puche, Julia

International journal of antimicrobial agents

2024 , Page(s) 107210

Language	English
Publishing date	2024-05-18
Publishing country	Netherlands
Document type	Letter
ZDB-ID	1093977-5
ISSN	1872-7913 ; 0924-8579
ISSN (online)	1872-7913
ISSN	0924-8579
DOI	10.1016/j.ijantimicag.2024.107210
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3368: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 500: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Characterization of group A beta-haemolytic streptococcus with mucoid phenotype isolated in a tertiary hospital.

Guzmán-Puche, Julia / Tejero-Garcia, Rocio / Villalón, Pilar / Pino-Rosa, Silvia / Martínez-Martínez, Luis

Enfermedades infecciosas y microbiologia clinica (English ed.)

2022 Volume 40, Issue 7, Page(s) 381–384

Abstract: Introduction: The objective of this study is to characterize Streptococcus pyogenes isolates with a mucoid phenotype and to compare them with non-mucoid isolates obtained between April and August 2016.: Material and methods: Identification and ... ...

Abstract	Introduction: The objective of this study is to characterize Streptococcus pyogenes isolates with a mucoid phenotype and to compare them with non-mucoid isolates obtained between April and August 2016. Material and methods: Identification and antimicrobial susceptibility were performed in all isolates. The emm type and exotoxin genes speA, speB, speC, speF, speG, speH, speJ, speZ and ssa were analyzed. Clinical and demographic data were collected. Results: From 96 isolates analyzed, 47% had a mucoid phenotype and 95.5% of them presented speA-speB-speF-speG-ssa genes and emm3 genotype. The main clinical manifestation was pharyngotonsillitis (77.1%) evolving to scarlet fever in 67.5% of the cases. Conclusion: This study describes the circulation of a mucoid phenotype strain with a speA-speB-speF-speG-ssa toxin profile and emm3.1 genotype considered one of the most frequent and virulent of SGA.
MeSH term(s)	Antigens, Bacterial/genetics ; Humans ; Phenotype ; Streptococcal Infections ; Streptococcus pyogenes/genetics ; Tertiary Care Centers
Chemical Substances	Antigens, Bacterial
Language	English
Publishing date	2022-05-12
Publishing country	Spain
Document type	Journal Article
ISSN	2529-993X
ISSN (online)	2529-993X
DOI	10.1016/j.eimce.2022.04.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Characterization of group A beta-haemolytic streptococcus with mucoid phenotype isolated in a tertiary hospital.

Guzmán-Puche, Julia / Tejero-Garcia, Rocio / Villalón, Pilar / Pino-Rosa, Silvia / Martínez-Martínez, Luis

Enfermedades infecciosas y microbiologia clinica (English ed.)

2021

Title translation	Caracterización de estreptococos beta-hemolíticos del grupo A con fenotipo mucoide aislados en un hospital de tercer nivel.
Abstract	Introduction: The objective of this study is to characterize Streptococcus pyogenes isolates with a mucoid phenotype and to compare them with non-mucoid isolates obtained between April and August 2016. Material and methods: Identification and antimicrobial susceptibility were performed in all isolates. The emm type and exotoxin genes speA, speB, speC, speF, speG, speH, speJ, speZ and ssa were analyzed. Clinical and demographic data were collected. Results: From 96 isolates analyzed, 47% had a mucoid phenotype and 95.5% of them presented speA-speB-speF-speG-ssa genes and emm3 genotype. The main clinical manifestation was pharyngotonsillitis (77.1%) evolving to scarlet fever in 67.5% of the cases. Conclusion: This study describes the circulation of a mucoid phenotype strain with a speA-speB-speF-speG-ssa toxin profile and emm3.1 genotype considered one of the most frequent and virulent of SGA.
Language	Spanish
Publishing date	2021-02-13
Publishing country	Spain
Document type	Journal Article
ISSN	2529-993X
ISSN (online)	2529-993X
DOI	10.1016/j.eimc.2020.12.015
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria

Fuente, Carmen de la / Rodríguez, Marina / Merino, Noemí / Carmona, Purificación / Machuca, Isabel / Córdoba-Fernández, María / Guzmán-Puche, Julia / Domínguez, Arantxa / López-Viñau, Teresa / Garcia, Lucrecia / Vaquero, José Manuel / Robles Ibarra, Juan Carlos / Martínez Martínez, Luis / Torre-Cisneros, Julián

International Journal of Antimicrobial Agents. 2023 July, v. 62, no. 1 p.106818-

2023

Abstract: Treatment of infections caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) is challenging and new active antibiotics are needed urgently. This study describes the efficacy and safety of cefiderocol in a retrospective series of 13 patients ... ...

Abstract	Treatment of infections caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) is challenging and new active antibiotics are needed urgently. This study describes the efficacy and safety of cefiderocol in a retrospective series of 13 patients with severe CR-GNB infection and limited treatment options. Pseudomonas aeruginosa was the predominant CR-GNB (n=8), followed by Burkholderia cepacia (n=3), Sthenotrophomona maltophilia (n=1) and KPC-producing Klebsiella pneumoniae (n=1). The source of infection was nosocomial pneumonia in 92.3% of cases (12/13), of which 11 cases were ventilator-associated pneumonia. Five patients were lung transplant recipients (38.5%). The median duration of treatment was 10 days (range 6–21 days). No severe adverse effects required reducing the dose or interrupting the treatment. Clinical and microbiological cure were assessed 7 days after the end of treatment, and achieved in 84.6% (11/13) of patients. Crude mortality at day 28 was observed in 23.1% (3/13) of cases. Cefiderocol is a valid alternative for the treatment of susceptible CR-GNB infections in patients with limited therapeutic options.
Keywords	Burkholderia cepacia ; Klebsiella pneumoniae ; Pseudomonas aeruginosa ; cross infection ; lungs ; mortality ; pneumonia ; therapeutics ; Cefiderocol ; Multiresistance ; Lung transplantation
Language	English
Dates of publication	2023-07
Publishing place	Elsevier Ltd
Document type	Article ; Online
Note	Pre-press version
ZDB-ID	1093977-5
ISSN	1872-7913 ; 0924-8579
ISSN (online)	1872-7913
ISSN	0924-8579
DOI	10.1016/j.ijantimicag.2023.106818
Database	NAL-Catalogue (AGRICOLA)

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3368: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 500: Show issues

Order via subito

Details ▾

Article ; Online: Characterization of OXA-48-producing Klebsiella oxytoca isolates from a hospital outbreak in Tunisia.

Guzmán-Puche, Julia / Jenayeh, Rim / Pérez-Vázquez, María / Manuel-Causse / Asma, Ferjani / Jalel, Boukadida / Oteo-Iglesias, Jesús / Martínez-Martínez, Luis

Journal of global antimicrobial resistance

2021 Volume 24, Page(s) 306–310

Abstract: Objective: There is very limited information about OXA-48-producing Klebsiella oxytoca. The aim of this study was to describe the phenotypic and molecular characterization of OXA-48-producing K. oxytoca isolates that caused an outbreak in a hospital in ... ...

Abstract	Objective: There is very limited information about OXA-48-producing Klebsiella oxytoca. The aim of this study was to describe the phenotypic and molecular characterization of OXA-48-producing K. oxytoca isolates that caused an outbreak in a hospital in Tunisia. Methods: Nineteen OXA-48-producing K. oxytoca were isolated from 2013 to 2016 in the University Hospital Farhat Hached, Sousse, Tunisia. Antibiotic susceptibility testing was performed by broth microdilution. Carbapenemase activity was investigated using the modified carbapenem inactivation method (mCIM). Phenotypic tests were also carried out to detect extended-spectrum β-lactamases. PCR was used to test for the presence of carbapenemase genes (bla Results: mCIM was positive in all isolates. None of the isolates presented an ESBL phenotype. All strains were susceptible to cefoxitin, ceftazidime, cefepime, aztreonam, imipenem, meropenem, fluoroquinolones, aminoglycosides and colistin, and resistant to piperacillin-tazobactam, ertapenem, ticarcillin and ampicillin-sulbactam. All isolates presented the bla Conclusion: Isolates from this study did not co-express an ESBL, which could complicate their detection in clinical laboratories. As OXA-48 has been mostly reported in K. pneumoniae there is a risk that the production of this enzyme is not suspected in the less common species K. oxytoca. These difficulties could play an important role in the hidden spread of this enzyme.
MeSH term(s)	Disease Outbreaks ; Drug Resistance, Bacterial ; Hospitals ; Humans ; Klebsiella oxytoca/genetics ; Microbial Sensitivity Tests ; Tunisia/epidemiology ; beta-Lactamases/genetics
Chemical Substances	beta-Lactamases (EC 3.5.2.6)
Language	English
Publishing date	2021-02-02
Publishing country	Netherlands
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2710046-7
ISSN	2213-7173 ; 2213-7173
ISSN (online)	2213-7173
ISSN	2213-7173
DOI	10.1016/j.jgar.2021.01.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: ZHO-1, an intrinsic MBL from the environmental Gram-negative species Zhongshania aliphaticivorans.

Kieffer, Nicolas / Guzmán-Puche, Julia / Poirel, Laurent / Kang, Hyo Jung / Jeon, Che Ok / Nordmann, Patrice

The Journal of antimicrobial chemotherapy

2019 Volume 74, Issue 6, Page(s) 1568–1571

Abstract: Objectives: Our aim was to characterize the putative MBL of the environmental strain Zhongshania aliphaticivorans isolated from a marine environment.: Methods: The putative MBL was identified in silico using the NCBI database. The β-lactamase gene ... ...

Abstract	Objectives: Our aim was to characterize the putative MBL of the environmental strain Zhongshania aliphaticivorans isolated from a marine environment. Methods: The putative MBL was identified in silico using the NCBI database. The β-lactamase gene was cloned into different Escherichia coli backgrounds. Kinetic parameters were determined using the purified enzyme. Results: The enzyme named ZHO-1 shared 51% amino acid identity with the acquired class B carbapenemases IMP-1, KHM-1 and DIM-1. Expression of the blaZHO-1 gene in a susceptible E. coli resulted in a carbapenemase phenotype. Kinetic parameters determined from purified ZHO-1 enzyme showed that it had significant hydrolytic activity against most β-lactams including penicillins, cephalosporins and carbapenems, with the exception of aztreonam and cefepime. Conclusions: This study adds to the knowledge regarding environmental species as a reservoir of possible clinically relevant MBLs.
MeSH term(s)	Amino Acid Sequence ; Anti-Bacterial Agents/pharmacology ; Bacterial Proteins/chemistry ; Bacterial Proteins/genetics ; Bacterial Proteins/metabolism ; Cloning, Molecular ; Drug Resistance, Multiple, Bacterial/genetics ; Gammaproteobacteria/drug effects ; Gammaproteobacteria/enzymology ; Gene Expression Regulation, Bacterial ; beta-Lactamases/genetics ; beta-Lactamases/metabolism
Chemical Substances	Anti-Bacterial Agents ; Bacterial Proteins ; beta-Lactamases (EC 3.5.2.6)
Language	English
Publishing date	2019-02-18
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkz057
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria.

de la Fuente, Carmen / Rodríguez, Marina / Merino, Noemí / Carmona, Purificación / Machuca, Isabel / Córdoba-Fernández, María / Guzmán-Puche, Julia / Domínguez, Arantxa / López-Viñau, Teresa / García, Lucrecia / Vaquero, José Manuel / Robles, Juan Carlos / Martínez-Martínez, Luis / Torre-Cisneros, Julián

International journal of antimicrobial agents

2023 Volume 62, Issue 1, Page(s) 106818

Abstract	Treatment of infections caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) is challenging and new active antibiotics are needed urgently. This study describes the efficacy and safety of cefiderocol in a retrospective series of 13 patients with severe CR-GNB infection and limited treatment options. Pseudomonas aeruginosa was the predominant CR-GNB (n=8), followed by Burkholderia cepacia (n=3), Sthenotrophomona maltophilia (n=1) and KPC-producing Klebsiella pneumoniae (n=1). The source of infection was nosocomial pneumonia in 92.3% of cases (12/13), of which 11 cases were ventilator-associated pneumonia. Five patients were lung transplant recipients (38.5%). The median duration of treatment was 10 days (range 6-21 days). No severe adverse effects required reducing the dose or interrupting the treatment. Clinical and microbiological cure were assessed 7 days after the end of treatment, and achieved in 84.6% (11/13) of patients. Crude mortality at day 28 was observed in 23.1% (3/13) of cases. Cefiderocol is a valid alternative for the treatment of susceptible CR-GNB infections in patients with limited therapeutic options.
MeSH term(s)	Humans ; Carbapenems/therapeutic use ; Carbapenems/pharmacology ; Retrospective Studies ; Salvage Therapy ; Cephalosporins/therapeutic use ; Cephalosporins/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Gram-Negative Bacteria ; Gram-Negative Bacterial Infections/microbiology ; Cefiderocol
Chemical Substances	Carbapenems ; Cephalosporins ; Anti-Bacterial Agents
Language	English
Publishing date	2023-04-14
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1093977-5
ISSN	1872-7913 ; 0924-8579
ISSN (online)	1872-7913
ISSN	0924-8579
DOI	10.1016/j.ijantimicag.2023.106818
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3368: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 500: Show issues

Order via subito

Details ▾

Article ; Online: Community-acquired bacteraemia by Klebsiella pneumoniae producing KPC-3 and resistant to ceftazidime/avibactam.

Machuca, Isabel / Guzmán-Puche, Julia / Pérez-Nadales, E / Gracia-Ahufinger, I / Mendez, A / Cano, A / Castón, J J / Domínguez, A / Torre-Cisneros, J / Martínez-Martínez, L

Journal of global antimicrobial resistance

2022 Volume 30, Page(s) 399–402

Abstract: Objectives: To describe the clinical and microbiological features of a case of community-acquired infection by KPC-producing K. pneumoniae (KPCKP) resistant to ceftazidime/avibactam (CAZ-AVI).: Methods: Identification of microorganisms was performed ... ...

Abstract	Objectives: To describe the clinical and microbiological features of a case of community-acquired infection by KPC-producing K. pneumoniae (KPCKP) resistant to ceftazidime/avibactam (CAZ-AVI). Methods: Identification of microorganisms was performed with MALDI Biotyper CA System (BrukerDaltonics, Madrid, Spain). Antimicrobial susceptibility testing was performed using Sensitre EURGNCOL panels (Thermo Fisher Scientific, Madrid, Spain) and gradient strips (Etest, bioMérieux, Madrid, Spain) in the case of CAZ-AVI, using EUCAST breakpoints for interpretation. Whole genome sequencing of blood culture and rectal swab isolates was performed using the Illumina NovaSeq 6000 sequencing system, with 2 × 150-bp paired-end reads (Illumina, Inc.). Results: Blood culture and rectal swab KPCKP isolates were resistant to carbapenems and to CAZ-AVI. The blood culture isolate showed susceptibility to trimethoprim-sulfamethoxazole (TMP-SMX), but the rectal swab culture isolate was resistant to this antibiotic. Both isolates belonged to clonal lineage ST512, harboured a single copy of bla Conclusions: Resistance to ceftazidime-avibactam is an emerging nosocomial problem. This case shows that CAZ-AVI-resistant KPCKP strains may disseminate into the community and cause serious infections.
MeSH term(s)	Azabicyclo Compounds ; Bacteremia ; Ceftazidime/pharmacology ; Drug Combinations ; Humans ; Klebsiella Infections/microbiology ; Klebsiella pneumoniae/genetics ; Microbial Sensitivity Tests ; Trimethoprim, Sulfamethoxazole Drug Combination
Chemical Substances	Azabicyclo Compounds ; Drug Combinations ; avibactam, ceftazidime drug combination ; avibactam (7352665165) ; Trimethoprim, Sulfamethoxazole Drug Combination (8064-90-2) ; Ceftazidime (9M416Z9QNR)
Language	English
Publishing date	2022-07-22
Publishing country	Netherlands
Document type	Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2710046-7
ISSN	2213-7173 ; 2213-7173
ISSN (online)	2213-7173
ISSN	2213-7173
DOI	10.1016/j.jgar.2022.07.017
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Randomised, double-blind, placebo-controlled, phase 2, superiority trial to demonstrate the effectiveness of faecal microbiota transplantation for selective intestinal decolonisation of patients colonised by carbapenemase-producing

Pérez-Nadales, Elena / Cano, Ángela / Recio, Manuel / Artacho, María José / Guzmán-Puche, Julia / Doblas, Antonio / Vidal, Elisa / Natera, Clara / Martínez-Martínez, Luis / Torre-Cisneros, Julian / Castón, Juan José

BMJ open

2022 Volume 12, Issue 4, Page(s) e058124

Abstract: Introduction: Infections caused by carbapenemase-producing : Methods and analysis: The KAPEDIS trial is a single-centre, randomised, double-blind, placebo-controlled, phase 2, superiority clinical trial of FMT for eradication of intestinal ... ...

Abstract	Introduction: Infections caused by carbapenemase-producing Methods and analysis: The KAPEDIS trial is a single-centre, randomised, double-blind, placebo-controlled, phase 2, superiority clinical trial of FMT for eradication of intestinal colonisation by KPC-Kp. One hundred and twenty patients with rectal colonisation by KPC-Kp will be randomised 1:1 to receive encapsulated lyophilised FMT or placebo. The primary outcome is KPC-Kp eradication at 30 days. Secondary outcomes are: (1) frequency of adverse events; (2) changes in KPC-Kp relative load within the intestinal microbiota at 7, 30 and 90 days, estimated by real-time quantitative PCR analysis of rectal swab samples and (3) rates of persistent eradication, KPC-Kp infection and crude mortality at 90 days. Participants will be monitored for adverse effects throughout the intervention. Ethics and dissemination: Ethical approval was obtained from Reina Sofía University Hospital Institutional Review Board (approval reference number: 2019-003808-13). Trial results will be published in peer-reviewed journals and disseminated at national and international conferences. Trial registration number: NCT04760665.
MeSH term(s)	Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Bacterial Proteins ; Carbapenem-Resistant Enterobacteriaceae ; Fecal Microbiota Transplantation/methods ; Humans ; Klebsiella Infections/drug therapy ; Klebsiella pneumoniae ; beta-Lactamases
Chemical Substances	Anti-Bacterial Agents ; Bacterial Proteins ; beta-Lactamases (EC 3.5.2.6) ; carbapenemase (EC 3.5.2.6)
Language	English
Publishing date	2022-04-06
Publishing country	England
Document type	Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	2599832-8
ISSN	2044-6055 ; 2044-6055
ISSN (online)	2044-6055
ISSN	2044-6055
DOI	10.1136/bmjopen-2021-058124
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Hidden dissemination of carbapenem-susceptible OXA-48-producing Proteus mirabilis.

Pedraza, Rosa / Kieffer, Nicolas / Guzmán-Puche, Julia / Artacho, María José / Pitart, Cristina / Hernández-García, Marta / Vila, Jordi / Cantón, Rafael / Martinez-Martinez, Luis

The Journal of antimicrobial chemotherapy

2022 Volume 77, Issue 11, Page(s) 3009–3015

Abstract: Objectives: To detect a potential hidden dissemination of the blaOXA-48 gene among Proteus mirabilis isolates obtained from a single centre.: Methods: P. mirabilis from diverse clinical samples presenting an ESBL phenotype or obtained from blood ... ...

Abstract	Objectives: To detect a potential hidden dissemination of the blaOXA-48 gene among Proteus mirabilis isolates obtained from a single centre. Methods: P. mirabilis from diverse clinical samples presenting an ESBL phenotype or obtained from blood cultured from 2017 to 2019 were evaluated. Bacterial identification was performed using MALDI-TOF MS. MICs were determined using International Organization for Standardization (ISO) standard microdilution and interpreted following EUCAST guidelines. WGS was performed using both short- and long-read technologies and assemblies were done using Unicycler. Resistomes were assessed using the ResFinder database. SNPs were detected using the PATRIC bioinformatics platform. Cloning experiments were performed using the pCRII-TOPO cloning kit. Results: Thirty-one out of 108 (28.7%) isolates were positive for blaOXA-48 and blaCTX-M-15. Twenty-nine out of 31 of the isolates were susceptible to temocillin, piperacillin/tazobactam, ertapenem and meropenem, whereas only 2/31 showed a resistance phenotype against these antibiotics. Both blaOXA-48 and blaCTX-M-15 genes were detected within the same chromosomally integrated new transposon in all isolates. The resistant isolates displayed a single mutation located in the putative promoter upstream of blaOXA-48. Cloning experiments confirmed that the mutation was responsible for the resistance phenotype. Conclusions: The presence of a chromosomal copy of blaOXA-48 did not confer resistance to carbapenems, but a single mutation in the promoter could lead to an increase in resistance. This study shows a hidden circulation of OXA-48-positive, but carbapenem- and piperacillin/tazobactam-susceptible, P. mirabilis isolates that can become resistant to β-lactams after a single mutation.
MeSH term(s)	Carbapenems/pharmacology ; Proteus mirabilis/genetics ; beta-Lactamases/genetics ; Microbial Sensitivity Tests ; Anti-Bacterial Agents/pharmacology ; Piperacillin, Tazobactam Drug Combination
Chemical Substances	Carbapenems ; beta-Lactamases (EC 3.5.2.6) ; Anti-Bacterial Agents ; Piperacillin, Tazobactam Drug Combination (157044-21-8)
Language	English
Publishing date	2022-08-15
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkac267
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito